RxDoctor Payments Data

Shrikant Vaidya, MD

Urology · Point Pleasant, WVNPI 1316082555

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Axonics, Inc. at 51.9% of the total. Reporting peaked in 2021 at $1,583 and has fallen 93.7% since, to $100 in 2024. That places this record below the midpoint for urology clinicians in WV, where the typical reported total is $2,534.

$2,556in general payments, 2019–2025

Across 37 payments — averaging $69.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$602
  • Endo Pharmaceuticals Inc.$284
  • Pfizer$87
  • Boston Scientific$63
  • Johnson & Johnson$40
  • plus $153 from 6 others

What the payments were for

  • Travel & lodging$95537%
  • Food & beverage$1,09243%
  • Education$50920%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,556 in reported general payments places this provider in the 50th percentile of 67 urology providers in West Virginia.

See all urology providers in West Virginia

Medicare billing

Part B allowed, 2024
$33,757
Medicare patients
136
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron16$11,631
Solifenacin Succinate17$2,546
Oxybutynin Chloride ErOxybutynin Chloride88$1,852
Tamsulosin Hcl125$1,352
Finasteride87$1,187
Testosterone Cypionate15$590
Cephalexin88$395
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$201
Ciprofloxacin Hcl13$95
Phenazopyridine Hcl11$78
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$602$11,63116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 67 urology providers in West Virginia.

Other urology in Point Pleasant

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →